Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Evaluating the Effects of Olanzapine on Brain Insulin Signaling and Cognitive Outcomes
FY 2019-20
Summary
"Antipsychotic (APs) medications are the cornerstone of schizophrenia treatment. Unfortunately, APs have been associated with serious metabolic adverse effects, including weight gain and type 2 diabetes. These metabolic abnormalities are also associated with poorer cognitive function, and may worsen pre-existing cognitive dysfunction in schizophrenia. The mechanisms underlying AP effects on glucose metabolism dysregulation and cognition are largely unknown. Animal studies have shown that an acute dose of olanzapine, an AP with high metabolic liability, can completely abolish the well-known ability of a brain insulin stimulus to decrease hepatic glucose production in rats. This suggests that olanzapine can induce resistance to insulin action in the brain. The concept of brain insulin resistance has recently been proposed to explain the link between cognitive and metabolic disorders. Inducing brain insulin resistance may be a potential mechanism through which metabolic adverse effects and lack of improvement in cognition occur during AP treatment. As such, the objective of this study is two-fold. First, we will examine if intranasal insulin increases glutamate levels in the striatum and dorsolateral prefrontal cortex, improves visuospatial task performance, and changes cerebral blood flow to the aforementioned brain regions, compared to intranasal placebo. Second, we will investigate whether olanzapine acutely inhibits intranasal insulin associated changes in brain functioning and cognitive outcomes. This work aims to shed light on the mechanisms behind metabolic adverse effects of AP drugs and their cognitive effects and has the potential to initiate new streams of work in an area of significant unmet need, potentially leading to new therapeutic strategies."
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
429065
Name
Stogios Nicolette
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the Effects of Olanzapine on Brain Insulin Signaling and Cognitive Outcomes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antipsychotics; Cognition; Functional Mri; Glucose Metabolism; Intranasal Insulin
Abstract
"Antipsychotic (APs) medications are the cornerstone of schizophrenia treatment. Unfortunately, APs have been associated with serious metabolic adverse effects, including weight gain and type 2 diabetes. These metabolic abnormalities are also associated with poorer cognitive function, and may worsen pre-existing cognitive dysfunction in schizophrenia. The mechanisms underlying AP effects on glucose metabolism dysregulation and cognition are largely unknown. Animal studies have shown that an acute dose of olanzapine, an AP with high metabolic liability, can completely abolish the well-known ability of a brain insulin stimulus to decrease hepatic glucose production in rats. This suggests that olanzapine can induce resistance to insulin action in the brain. The concept of brain insulin resistance has recently been proposed to explain the link between cognitive and metabolic disorders. Inducing brain insulin resistance may be a potential mechanism through which metabolic adverse effects and lack of improvement in cognition occur during AP treatment. As such, the objective of this study is two-fold. First, we will examine if intranasal insulin increases glutamate levels in the striatum and dorsolateral prefrontal cortex, improves visuospatial task performance, and changes cerebral blood flow to the aforementioned brain regions, compared to intranasal placebo. Second, we will investigate whether olanzapine acutely inhibits intranasal insulin associated changes in brain functioning and cognitive outcomes. This work aims to shed light on the mechanisms behind metabolic adverse effects of AP drugs and their cognitive effects and has the potential to initiate new streams of work in an area of significant unmet need, potentially leading to new therapeutic strategies."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Stogios, Nicolette
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~